Since its enactment, the Hatch-Waxman Act has been continuously encouraging generic drug manufacturers to challenge active drug patents and gain market entry before the patents’ expected nominal expiration dates.
In the past several years, the number of lawsuits involving Paragraph IV challenges has significantly increased and the outcome of each litigation varies significantly according to the type of patent challenged.
In this webinar, organized by the Knowledge Group, a team of thought leaders and professionals will provide the audience with an in-depth analysis of the important issues and trends surrounding Paragraph IV challenges. Speakers will also present key strategies and practical tips to avoid common risks and pitfalls surrounding this significant topic.
Key Topics Include:
- Paragraph IV Challenges in the 2017 Landscape
- Recent Court Decisions
- Scope and Limitations
- Common Risks and Pitfalls
- Recent Trends, Developments, and Updates